Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;104(4):299-309.
doi: 10.1111/ejh.13375. Epub 2020 Jan 24.

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia

Nicola Gökbuget  1 , Hervé Dombret  2 , Sebastian Giebel  3 , Monika Brüggemann  4 , Michael Doubek  5 , Robin Foa  6 , Dieter Hoelzer  7 , Christopher Kim  8 , Giovanni Martinelli  9 , Elena Parovichnikova  10 , Josep Maria Ribera  11 , Marieke Schoonen  12 , Catherine Tuglus  13 , Gerhard Zugmaier  14 , Renato Bassan  15
Affiliations

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia

Nicola Gökbuget et al. Eur J Haematol. 2020 Apr.

Erratum in

Abstract

Objectives: Survival outcomes from a single-arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)-positive B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set.

Methods: The primary analysis comprised adult Philadelphia chromosome (Ph)-negative patients in first complete haematologic remission (MRD ≥ 10-3 ). Relapse-free survival (RFS) and overall survival (OS) were compared between blinatumomab- and SOC-treatment groups. Baseline differences between groups were adjusted by propensity scores.

Results: The primary analysis included 73 and 182 patients from the blinatumomab and historic data sets, respectively. When weighted by age to the blinatumomab-treatment group, median RFS was 7.8 months and median OS was 25.9 months in the SOC-treated group. In the blinatumomab study, median RFS was 35.2 months; median OS was not evaluable. Propensity score weighting achieved balance with seven baseline prognostic factors. With adjustment for haematopoietic stem cell transplantation (HSCT) status, a 50% reduction in risk of relapse or death was observed with blinatumomab vs SOC. Median RFS, unadjusted for HSCT status, was 35.2 months with blinatumomab and 8.3 months with SOC.

Conclusions: These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.

Keywords: acute lymphoblastic leukaemia; clinical trials.

PubMed Disclaimer

Conflict of interest statement

NG has received honoraria and research funding and has served on advisory boards, for Amgen, Pfizer, Celgene and Novartis; HD has received honoraria and/or research funding from Amgen, Agios, Seattle Genetics, Celgene, Sunesis, Roche, Pfizer, Ambit‐Daiichi Sankyo, Shire‐Baxalta, Ariad‐Incyte, Karyopharm, Abbvie, Novartis, Kite, Otsuka, Celator‐Jazz, Astellas, Menarini, Cellectis, Janssen, ImmunoGen and Servier; SG has received honoraria and has served on advisory boards for Amgen; MB has received honoraria and has served on advisory boards and at Speaker Bureaus for Amgen, Hoffman‐La Roche and Incyte, and has received grant/research support from Affimed Therapeutics, Amgen Research, Celgene and Regeneron; MD has received honoraria and/or research funding from AbbVie, Amgen, AOP Orphan, Gilead, Janssen‐Cilag, Novartis and Roche; RF has served on advisory boards and at Speaker Bureaus for Janssen, AbbVie, Celgene, Novartis, Amgen, Pfizer and Servier; DH declares no conflicts of interest; CK, MS, CT and GZ are employees and stockholders of Amgen; GM has served as an adviser to Amgen, Ariad/Incyte, Pfizer, Roche, Celgene, Janssen and Jazz Pharmaceuticals, and on Speaker Bureaus for Novartis, Pfizer and Celgene, and has received travel compensation from Daiichi Sankyo, Roche and Shire; EP has received research funds from Abbvie, Roche, Amgen, Novartis and Bristol; JMR has received honoraria and research funds and has served on advisory boards, for Amgen, Pfizer, Shire and Ariad; RB has received honoraria and has served on advisory boards for Amgen, Pfizer, Shire and Incyte.

Figures

Figure 1
Figure 1
Kaplan‐Meier curve of relapse‐free survival for the primary analysis set after propensity score adjustment using stabilised inverse probability of treatment weighting. CI, confidence interval; HR, hazard ratio; NE, not evaluable; RFS, relapse‐free survival; SOC, standard of care
Figure 2
Figure 2
Kaplan‐Meier curve of overall survival for the primary analysis set after propensity score adjustment using stabilised inverse probability of treatment weighting. CI, confidence interval; HR, hazard ratio; NE, not evaluable; OS, overall survival; SOC, standard of care
See this image and copyright information in PMC

References

    1. Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1:2456‐2466. - PMC - PubMed
    1. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120:4470‐4481. - PubMed
    1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532‐543. - PubMed
    1. Moppett J, Burke GA, Steward CG, Oakhill A, Goulden NJ. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. J Clin Pathol. 2003;56:249‐253. - PMC - PubMed
    1. Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24:521‐535. - PubMed

Grants and funding